Purdue Pharma launches no-profit treatment to reverse opioid overdose effects

Five months after the FDA approved Purdue Pharma's opioid antagonist injection, nalmefene hydrochloride, the no-profit treatment is now available for use, according to a June 21 press release

Nalmefene hydrochloride is for a "complete or partial reversal of opioid drug effects," such as respiratory depression, the press release said.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Whitepapers

Featured Webinars